Dok, I understand the point about the $5 requirement and agree that uplisting will be beneficial in getting institutional investors with more clout. My comment was about Big Pharma trying to partner with Anavex for the purpose of getting a percentage of sales or buying them out regardless of the exchange.
I agree with you 100% about uplisting making Anavex more desirable and a safer investment in the eyes of future shareholders (institutional or otherwise).
News 
Market Data 
Discover 
AI
